Background: Avelumab is a human anti-PD-L1 IgG1 antibody that has shown promising clinical activity in multiple tumor types, and is approved in the US for the treatment of metastatic Merkel cell carcinoma. Here, we report an updated analysis of avelumab in patients (pts) with mACC, representing the largest prospective monotherapy study performed to date in this rare cancer with limited therapeutic options. Methods: In a phase 1b cohort (NCT01772004), pts with mACC and prior platinumbased therapy received avelumab at 10 mg/kg IV Q2W until progression, unacceptable toxicity, or withdrawal. Prior and ongoing treatment with mitotane was permitted. Tumors were assessed every 6 wks (RECIST v1.1). Endpoints included safety (NCI-CTCAE v4.0), best overall response, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: As of Dec 31, 2016, 50 pts from 6 countries received avelumab for a median of 3.4 mos (0.5-24.8). Median follow-up was 16.5 mos (11.7-27.6); 5 pts (10.0%) remained on treatment. Median age was 50 y (range 21-71) and median time since diagnosis of metastatic disease was 14.5 mos. 24 pts (48.0%) had received !2 prior lines of treatment for advanced disease (median 1, range 0-6). 41 pts (82.0%) had a treatmentrelated adverse event (TRAE) of any grade; the most common (>15%) were nausea (20.0%) and fatigue (18.0%). 8 pts (16.0%) had a grade !3 TRAE, of which only increased ALT (4.0%) occurred in > 1 pt. 12 pts (24.0%) had an immune-related AE of any grade. Confirmed ORR was 6.0% (3 partial responses; 95% CI 1.3-16.5); response was ongoing in 1 pt at data cutoff. 21 pts (42.0%) had stable disease as best response (disease control rate 48.0%). Median PFS was 2.6 mos (95% CI 1.4-4.0). Median OS was 10.6 mos (95% CI 7.4-not estimable) and the 12-mo OS rate was 47.0% (95% CI 31.8-60.9). Responses occurred in 2 pts with PD-L1þ tumors and 1 PD-L1 À (!5% tumor cell cutoff). In PD-L1 þ (n ¼ 12) vs PD-L1 À (n ¼ 30) subgroups, median PFS was 5.5 vs 1.7 mos (HR 0.66; 95% CI 0.3-1.4) and median OS was 14.4 vs 11.5 mos (HR 0.82; 95% CI 0.3-2.2), respectively. Conclusions: Avelumab had a manageable safety profile and demonstrated clinical activity in pts with platinum-treated mACC.
914P Do patients (pts) with advanced nonseminomatous germ cell tumors (aNSGCT) and unfavorable time to normalization (TTN) of tumor markers benefit with prolongation of 1-st line chemotherapy (ChT)? Background: Three-four cycles of BEP are commonly recognized as a standard 1-st line ChT in aNSGCT. However, there were no trials studying optimal cycles numbers in this setting, especially in case of unfavorable TTN of tumor markers. We performed retrospective single center analysis to evaluate if pts with unfavorable TTN of tumor markers may benefit with prolongation of induction ChT. Methods: Inclusion criteria were as follows: (1) (Table) . 
